Novartis (NVS) announced Friday positive topline results from a phase 3 study evaluating the efficacy and safety of Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria who were switched from other therapies.
The company said that after 24 weeks of treatment with twice-daily oral monotherapy of the drug, also called iptacopan, average hemoglobin levels improved compared with the baseline.
Paroxysmal nocturnal hemoglobinuria is a rare, chronic blood disorder that causes the production of red blood cells susceptible to premature destruction, leading to anemia, blood clots, and fatigue among other symptoms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.